rosnilimab (ANB030) / AnaptysBio - LARVOL DELTA

ROSNILIMAB, A PD-1 AGONIST ANTIBODY IN CLINICAL DEVELOPMENT FOR ULCERATIVE COLITIS, REDUCES PATHOGENIC PD-1+ T CELLS AND INFLAMMATORY CYTOKINE SECRETION IN PATIENT SAMPLES AND IN A MOUSE MODEL OF COLITIS (DDW 2025) - No abstract available

Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

PHENOTYPING OF HUMAN UC COLONIC TISSUE REVEALS INFLAMMATORY PATHWAY GENE EXPRESSION IN PD-1+ CONVENTIONAL AND REGULATORY T CELLS WHICH OVERLAP WITH THOSE REGULATED BY ROSNILIMAB IN A MOUSE MODEL OF COLITIS (DDW 2025) - No abstract available

IO biomarker • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • PD-1

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Rosnilimab (PD-1 depleter and agonist): Presented preclinical data in Q4 2024 and Q1 2025...evaluating –The PD-1 depletion and agonism mechanisms of rosnilimab in vitro with UC patient-derived PBMCs and a mouse model of colitis at the 2024 United European Gastroenterology Week (UEGW). Inflammatory pathway gene expression in PD-1+ conventional and regulatory T cells in human UC tissue and rosnilimab’s effects in a mouse model of colitis at the European Crohn’s and Colitis Organisation (ECCO) Congress."

Preclinical • Ulcerative Colitis

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "ANB033 (CD122 antagonist): Enrollment ongoing for Phase 1a trial in healthy volunteers. Phase 1b indication to be disclosed at a 2025 R&D event. ANB101 (BDCA2 modulator): Phase 1a trial to initiate in healthy volunteers in Q1 2025....Research and development expenses were $42.6 million and $163.8 million for the three and twelve months ended December 31, 2024, compared to $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023. The increase was due primarily to development costs for rosnilimab, ANB032, ANB033 and ANB101 offset by a decrease in development costs for imsidolimab."

Commercial • New P1 trial • Trial status • Immunology

Phenotyping of human UC colonic tissue reveals inflammatory pathway gene expression in PD-1+ conventional and regulatory T cells which overlap with those regulated by rosnilimab in a mouse model of colitis (ECCO-IBD 2025) - P2 | "These additional analyses support preclinical findings and suggest beneficial modulation of gene expression pathways of human UC, including reduction of pro-inflammatory cytokines and fibrosis, and upregulation of barrier function genes. These data demonstrate that PD-1 is upstream of multiple clinically validated drivers of UC and support the scientific rationale for studying rosnilimab in an ongoing Phase 2 study in UC (NCT06127043)."

IO biomarker • Preclinical • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CCL20 • IL2RA • IL6 • MMP9 • PD-1 • TBX21

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire) - P2B | N=420 | RENOIR (NCT06041269) | Sponsor: AnaptysBio, Inc. | "Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo; Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA; Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA; 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28; Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses; Rosnilimab was safe and well tolerated with similar adverse event rates vs. placebo; Full Week 28 and additional translational RA data in Q2 2025; Top-line Week 12 Phase 2 ulcerative colitis data for rosnilimab, now in Q4 2025..."

P2 data • P2b data • Rheumatoid Arthritis • Ulcerative Colitis

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire) - "AnaptysBio...will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT."

P2b data • Rheumatoid Arthritis

Anticipate top-line Phase 2b data in rheumatoid arthritis…Phase 2 data in ulcerative colitis for rosnilimab... (GlobeNewswire) - "We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data in Q1 2026, followed by Phase 1b data from our two additional programs."

P2 data • P2b data • Rheumatoid Arthritis • Ulcerative Colitis

Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis (ACR Convergence 2024) - P2 | "PD-1 associated pathways were analyzed using Gene Set Variation Analysis (GSVA) on two gene sets: a nivolumab-induced gene set (Choueiri et al 2016), and a rosnilimab-induced gene set generated using RNA-seq data from purified T cells co-cultured with monocyte-derived DCs and rosnilimab. Synovial PD-1 and CXCL13 expression levels correlate with clinical markers of disease and persist across naïve, DMARD-IR, and TNF-IR patients with RA. This supports an important role for PD-1 in disease pathogenesis and the biologic rationale for using rosnilimab following different lines of therapy. This will be tested in the RENOIR study, an ongoing Phase 2 trial of rosnilimab in moderate/severe RA including biologic naïve and experienced patients (NCT06041269)."

Biomarker • IO biomarker • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CXCL13

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) (clinicaltrials.gov) - P2 | N=420 | Active, not recruiting | Sponsor: AnaptysBio, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2025 ➔ May 2025 | Trial primary completion date: Mar 2025 ➔ Nov 2024

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

ROSNILIMAB, A PD-1 AGONIST ANTIBODY IN CLINICAL DEVELOPMENT FOR ULCERATIVE COLITIS, REDUCES PATHOGENIC PD-1+ T CELLS AND INFLAMMATORY CYTOKINE SECRETION IN PATIENT BLOOD AND IN A MOUSE MODEL OF ULCERATIVE COLITIS (UEGW 2024) - P2 | "Rosnilimab, a PD-1 checkpoint agonist antibody, functions to reduce pathogenic PD-1+ T cells by both depletion and agonism. These in vivo and in vitro results are consistent with the mechanisms of depletion and agonism and support the strong rationale for evaluating the therapeutic potential of rosnilimab in an ongoing phase 2 study in UC."

Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CXCL13 • IFNG • IL12A

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire) - "AnaptysBio, Inc...today announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on Aug. 13, 2024. The gross proceeds from this offering are expected to be approximately $100 million, before deducting underwriting discounts, commissions and other offering expenses payable by Anaptys....Anaptys intends to use the net proceeds of this offering primarily for general corporate purposes, which may include funding Phase 3 enabling activities for ANB032 and rosnilimab, working capital and general corporate purposes. Sanofi did not receive rights to any of Anaptys’ programs as a part of their equity investment."

Financing • Atopic Dermatitis • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Updates on Wholly Owned ICM Pipeline: (i) ANB032 (BTLA agonist antibody): Completed enrollment for global Phase 2b trial in moderate-to-severe AD....Top-line Week 14 data expected in December 2024....(ii) Rosnilimab (PD-1 agonist antibody): Enrollment ongoing for global Phase 2b trial in moderate-to-severe RA....Top-line Week 12 data anticipated in Q1 2025....Enrollment ongoing for global Phase 2 trial in moderate-to-severe UC....Top-line Week 12 data anticipated in Q1 2026."

Enrollment closed • P2 data • P2b data • Atopic Dermatitis • Rheumatoid Arthritis • Ulcerative Colitis

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet? (PubMed, Gut) - "This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD."

Immune cell • Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Rosnilimab, a PD-1 Agonist Antibody That Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling (FOCIS 2024) - P2 | "Rosnilimab demonstrated greater reduction of T cell proliferation, inflammatory cytokines and genes related to T cell activation, and depletion of PD-1+ T cells compared to ref1 in vitro, consistent with the hypothesis that membrane proximal binding improves agonistic activity and target cell depletion. These mechanistic data, translational in vivo and in vitro data, robust Phase 1 healthy volunteer data, and unmet needs provide rationale for ongoing global Phase 2 studies of rosnilimab in RA (NCT06041269) and UC (NCT06127043)."

Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis

Rosnilimab, a PD-1 Agonist Antibody That Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling (FOCIS 2024) - P2 | "Rosnilimab demonstrated greater reduction of T cell proliferation, inflammatory cytokines and genes related to T cell activation, and depletion of PD-1+ T cells compared to ref1 in vitro, consistent with the hypothesis that membrane proximal binding improves agonistic activity and target cell depletion. These mechanistic data, translational in vivo and in vitro data, robust Phase 1 healthy volunteer data, and unmet needs provide rationale for ongoing global Phase 2 studies of rosnilimab in RA (NCT06041269) and UC (NCT06127043)."

Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis

OPTIMIZING PD-1 AGONIST SIGNALING WITH MEMBRANE PROXIMAL BINDING OF ROSNILIMAB, A CLINICAL STAGE PD-1 AGONIST IGG1 ANTIBODY (DDW 2024) - P2 | "Rosnilimab binds to a membrane proximal region of the PD-1 receptor, resulting in potent reduction of T cell proliferation and depletion of PD-1 high T cells. These mechanistic data, translational in vivo and in vitro data, robust Phase 1 healthy volunteer data, and unmet needs in UC provide rationale for an ongoing global Phase 2 study of rosnilimab in UC (NCT06127043)."

Clinical • IO biomarker • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Ulcerative Colitis • PTPRC

ROSNILIMAB, A NOVEL PD-1 AGONIST MONOCLONAL ANTIBODY, REDUCES T CELL PROLIFERATION, INFLAMMATORY CYTOKINE SECRETION, AND PD-1 [HIGH] EXPRESSING CD4 AND CD8 T CELLS: RESULTS FROM A PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL (DDW 2024) - P2 | "The role of PD-1 in UC pathophysiology coupled with these results and translational data demonstrate proof of mechanism and support progression into a Phase study of rosnilimab in UC. (NCT061 7043)"

Clinical • P1 data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD4 • CD8 • IFNG • PD-1

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectively...Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023. The increase was due primarily to development costs for rosnilimab..."

Commercial • Enrollment status • P2b data • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis • Ulcerative Colitis

Rosnilimab: Top-line data from P2 RENOIR trial (NCT06041269) for rheumatoid arthritis in mid-2025 (AnaptysBio) - Corporate Presentation

P2 data • Rheumatoid Arthritis

Rosnilimab: Protection of patents related to the antibody sequence of rosnilimab and its variants, methods of use and related matters until Jun 2040 (AnaptysBio) - Annual Report 2023

Patent • Inflammatory Bowel Disease • Rheumatoid Arthritis • Ulcerative Colitis

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) - "Enrollment ongoing for global Phase 2 trial in moderate-to-severe UC...Reiterating top-line Week 12 data anticipated by H1 2026...Research and development expenses were $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023, compared to $23.4 million and $88.8 million for the three and twelve months ended December 31, 2022. The increase was due primarily to manufacturing and development costs for rosnilimab, ANB032 and ANB033."

Commercial • Enrollment status • P2 data • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis • Ulcerative Colitis

Optimizing PD-1 agonist signaling with membrane proximal binding of rosnilimab, a clinical stage PD-1 agonist IgG1 antibody (ECCO-IBD 2024) - P2 | "Rosnilimab binds to a membrane proximal region of the PD-1 receptor, resulting in potent reduction of T cell proliferation and depletion of PD-1 high T cells. These mechanistic data, translational in vivo and in vitro data, robust Phase 1 healthy volunteer data, and unmet needs in UC provide rationale for an ongoing global Phase 2 study of rosnilimab in UC (NCT06127043)."

Clinical • IO biomarker • Inflammatory Bowel Disease • Ulcerative Colitis • PTPRC

Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trial (ECCO-IBD 2024) - P2 | "The role of PD-1 in UC pathophysiology coupled with these results and translational data, demonstrate proof of mechanism and support progression into a Phase 2 study of rosnilimab in UC. (NCT06127043)"

Clinical • P1 data • Inflammatory Bowel Disease • Ulcerative Colitis • CD4 • CD8 • IFNG • PD-1

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: AnaptysBio, Inc.

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis